STAT6-IN-9 is a potent STAT6 inhibitor with an EC 50 value of 4 nM. STAT6-IN-9 effectively blocks STAT6 activation mediated by the IL-13 -IL-13 receptor/ IL-4 receptor pathway. STAT6-IN-9 inhibits CCL17 secretion with an IC50 value of 4.6 nM. STAT6-IN-9 can be used to investigate various chronic inflammatory diseases mediated by STAT6, such as allergy, asthma, and chronic obstructive pulmonary disease [1].
In Vitro, STAT6-IN-9 (compound 6) potently inhibits STAT6-mediated reporter gene activity with an EC50 of 0.004 μM and suppresses CCL17 production in human whole blood with an IC50 of 0.046 μM[1].
References:
[1]. CHOl, Chuho, et al. Nitrogen-Contaning Heteroaryl Compounds for the Treatment of Chronic Diseases. Wo 2025/133961A1. World Intellectual Property Organization (WIPO) International Bureau. 26 June 2025.
In Vitro, STAT6-IN-9 (compound 6) potently inhibits STAT6-mediated reporter gene activity with an EC50 of 0.004 μM and suppresses CCL17 production in human whole blood with an IC50 of 0.046 μM[1].
References:
[1]. CHOl, Chuho, et al. Nitrogen-Contaning Heteroaryl Compounds for the Treatment of Chronic Diseases. Wo 2025/133961A1. World Intellectual Property Organization (WIPO) International Bureau. 26 June 2025.